- Home
- SQNS vs ACIU Comparison
SQNS vs ACIU Comparison
Compare SQNS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- ACIU
- Stock Information
- Founded
- SQNS 2003
- ACIU 2003
- Country
- SQNS France
- ACIU Switzerland
- Employees
- SQNS N/A
- ACIU N/A
- Industry
- SQNS Semiconductors
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- ACIU Health Care
- Exchange
- SQNS Nasdaq
- ACIU Nasdaq
- Market Cap
- SQNS 179.8M
- ACIU 213.3M
- IPO Year
- SQNS 2011
- ACIU 2016
- Fundamental
- Price
- SQNS $1.29
- ACIU $2.07
- Analyst Decision
- SQNS Strong Buy
- ACIU Strong Buy
- Analyst Count
- SQNS 2
- ACIU 1
- Target Price
- SQNS $5.50
- ACIU $12.00
- AVG Volume (30 Days)
- SQNS 7.7M
- ACIU 166.8K
- Earning Date
- SQNS 07-31-2025
- ACIU 08-05-2025
- Dividend Yield
- SQNS N/A
- ACIU N/A
- EPS Growth
- SQNS N/A
- ACIU N/A
- EPS
- SQNS 1.85
- ACIU N/A
- Revenue
- SQNS $37,325,000.00
- ACIU $36,362,036.00
- Revenue This Year
- SQNS N/A
- ACIU N/A
- Revenue Next Year
- SQNS $83.38
- ACIU $533.21
- P/E Ratio
- SQNS $0.69
- ACIU N/A
- Revenue Growth
- SQNS 32.07
- ACIU 86.71
- 52 Week Low
- SQNS $1.19
- ACIU $1.43
- 52 Week High
- SQNS $5.83
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- SQNS 38.33
- ACIU 46.16
- Support Level
- SQNS $1.25
- ACIU $2.05
- Resistance Level
- SQNS $1.37
- ACIU $2.50
- Average True Range (ATR)
- SQNS 0.17
- ACIU 0.19
- MACD
- SQNS -0.09
- ACIU -0.03
- Stochastic Oscillator
- SQNS 8.06
- ACIU 6.25
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.